VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IONS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IONSIonis Pharmaceuticals, Inc.
$27.39$4.6B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksIONSFinancials

Ionis Pharmaceuticals, Inc. (IONS) Income Statement

30Y historyFree accessUpdated daily

Revenue grew 54.9% year over year to $242.7M in 2026Q3 and gross margin held near 98.6%, but a -53.8% operating margin and a -45.3% net margin show that R&D intensity has kept profitability out of reach.

Income StatementBalance SheetCash FlowRatios

IONS Income Statement

Annual statement

IONS Income Statement

Ionis Pharmaceuticals, Inc. (IONS) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue959.76M944M705.14M787.65M587.37M810.46M729.26M1.12B599.67M514.18M372.78M283.7M214.16M147.28M102.05M99.09M108.47M121.6M107.19M58.34M14.86M40.13M42.62M49.99M80.18M53.27M37.26M33.9M39.2M32.7M22.7M
Revenue Growth %-0.74%33.87%-10.48%34.1%-27.53%11.13%-35.04%87.2%16.63%37.93%31.4%32.47%45.41%44.33%2.99%-8.65%-10.8%13.44%83.72%292.65%-62.98%-5.84%-14.73%-37.65%50.51%43%9.9%-13.52%19.88%44.05%74.62%
Cost of Goods Sold17.04M16M11.21M9.13M14.12M10.84M11.95M4.38M1.82M00322.29M241.75M184.03M158.46M00000000000-5.54M-5.2M-4.3M-3.2M-2.6M
COGS % of Revenue-1.69%1.59%1.16%2.4%1.34%1.64%0.39%0.3%--113.6%112.88%124.95%155.28%------------14.86%-15.34%-10.97%-9.79%-11.45%
Gross Profit942.72M928M693.92M778.51M573.25M799.61M717.32M1.12B597.85M514.18M372.78M-38.59M-27.59M-36.75M-56.41M99.09M108.47M121.6M107.19M000000042.79M39.1M43.5M35.9M25.3M
Gross Margin %98.22%98.31%98.41%98.84%97.6%98.66%98.36%99.61%99.7%100%100%-13.6%-12.88%-24.95%-55.28%100%100%100%100%-------114.86%115.34%110.97%109.79%111.45%
Gross Profit Growth %-33.73%-10.87%35.81%-28.31%11.47%-35.85%87.04%16.27%37.93%1066.02%-39.87%24.92%34.85%-156.93%-8.65%-10.8%13.44%--------100%9.44%-10.11%21.17%41.9%60.13%
Operating Expenses1.51B1.31B1.17B1.13B983.44M829.8M889.4M752.33M659.23M483.13M392.94M37.17M20.14M14.92M12.52M170.19M156.83M149.14M120.25M91.26M80.08M97.31M160.48M128.97M130.99M99.38M71.78M82.2M76M67.2M54.4M
OpEx % of Revenue-138.77%165.78%143.75%167.43%102.39%121.96%67.02%109.93%93.96%105.41%13.1%9.4%10.13%12.26%171.76%144.58%122.65%112.18%156.42%538.91%242.48%376.49%257.99%163.37%186.54%192.67%242.48%193.88%205.5%239.65%
Selling, General & Admin584.98M394M267.5M232.6M150.29M170.9M332.2M286.64M244.62M108.49M48.62M37.17M20.14M14.92M12.52M12.79M11.67M14.52M13.81M13.06M11.2M7.89M9.58M10.2M5.54M15.63M9.23M10.6M9.5M8.1M51.8M
SG&A % of Revenue-41.74%37.94%29.53%25.59%21.09%45.55%25.53%40.79%21.1%13.04%13.1%9.4%10.13%12.26%12.91%10.76%11.94%12.88%22.38%75.39%19.65%22.47%20.41%6.92%29.35%24.78%31.27%24.23%24.77%228.19%
Research & Development923.16M916M901.53M899.63M833M643M535M466M414.6M374.64M344.32M322.29M241.75M184.03M158.46M157.4M145.16M134.62M106.44M92.64M80.57M82.47M118.47M116.96M124.07M83.74M57.01M66.4M62.2M55.9M45.7M
R&D % of Revenue-97.03%127.85%114.22%141.82%79.34%73.36%41.51%69.14%72.86%92.37%113.6%112.88%124.95%155.28%158.85%133.82%110.71%99.3%158.78%542.21%205.48%277.95%233.97%154.75%157.19%153.04%195.87%158.67%170.95%201.32%
Other Operating Expenses00-26K19K147K15.9M22.2M-312K000-322.29M-241.75M-184.03M-158.46M00000-536K6.96M32.43M1.8M1.37M05.54M5.2M4.3M3.2M-43.1M
Operating Income-565.42M-382M-475.08M-353.73M-410.19M-30.19M-172.08M365.88M-61.37M31.05M-20.16M-75.76M-47.73M-51.67M-68.92M-71.1M-48.36M-27.54M-13.06M-32.92M-65.22M-57.18M-117.85M-78.98M-50.81M-46.1M-28.99M-43.1M-32.5M-31.3M-29.1M
Operating Margin %-58.91%-40.47%-67.37%-44.91%-69.84%-3.72%-23.6%32.59%-10.23%6.04%-5.41%-26.7%-22.29%-35.08%-67.54%-71.76%-44.58%-22.65%-12.18%-56.42%-438.91%-142.48%-276.49%-157.99%-63.37%-86.54%-77.82%-127.14%-82.91%-95.72%-128.19%
Operating Income Growth %-19.59%-34.31%13.76%-1258.88%82.46%-147.03%696.17%-297.67%254%73.39%-58.73%7.62%25.04%3.06%-47.03%-75.6%-110.86%60.33%49.52%-14.05%51.48%-49.22%-55.43%-10.22%-59.03%32.74%-32.62%-3.83%-7.56%-13.67%
EBITDA-543.52M-359.31M-453.09M-331.23M-388.09M-10.63M-154.92M381.88M-48.84M39.4M-11.13M-65.52M-38.33M-41.88M-58.17M-59.32M-39.18M-18.23M-6.24M-26.15M-58M-46.8M-105.68M-66.72M-41.39M-39.13M-23.45M-37.9M-28.2M-28.1M-26.5M
EBITDA Margin %-56.63%-38.06%-64.26%-42.05%-66.07%-1.31%-21.24%34.02%-8.15%7.66%-2.98%-23.1%-17.9%-28.44%-57%-59.86%-36.12%-15%-5.82%-44.83%-390.35%-116.6%-247.94%-133.48%-51.62%-73.46%-62.96%-111.8%-71.94%-85.93%-116.74%
EBITDA Growth %-111.14%20.7%-36.79%14.65%-3552.23%93.14%-140.57%881.83%-223.98%454.06%83.02%-70.96%8.49%28%1.93%-51.4%-114.86%-192.09%76.13%54.91%-23.94%55.72%-58.39%-61.21%-5.76%-66.85%38.11%-34.4%-0.36%-6.04%-16.23%
D&A (Non-Cash Add-back)21.89M22.69M21.99M22.5M22.11M19.56M17.16M15.99M12.53M8.35M9.03M10.24M9.4M9.78M10.76M11.78M9.18M9.3M6.82M6.76M7.22M10.38M12.17M12.25M9.42M6.97M5.54M5.2M4.3M3.2M2.6M
EBIT-495.43M-307M-375.71M-258.37M-249.86M-24.75M-128.35M351.21M-31.37M27.99M-18.67M-51.17M-32.18M-47.2M-53.44M-68.06M-47.93M-19.09M-2.71M-32.92M-65.75M-50.22M-85.43M-77.17M-49.44M-46.1M-28.99M-43.1M-32.5M-31.3M-29.1M
Net Interest Income13.92M7.22M16.57M7.58M17.21M695K21.05M3.44M-14.6M-36.57M-33.38M-32.43M-19.53M-17.27M-19.31M-14.32M-9.86M-6.31M5.71M3.87M-3.07M-15.22M-19.59M00000000
Interest Income89.99M97.77M107.02M89.04M25.33M10.04M30.56M52.2M30.19M8.18M5.42M4.3M2.68M2.08M1.84M2.41M3.37M6.36M11.32M11.44M5.96M5.09M3M00000000
Interest Expense76.07M90.54M90.45M81.46M8.12M9.35M9.51M48.77M44.79M44.75M38.8M36.73M22.21M19.36M21.15M16.73M13.23M12.67M5.6M7.57M9.03M20.31M22.59M00000000
Other Income/Expense21.61M2M15.01M19.77M152.21M1.04M37.53M-27.12M-14.78M-47.81M-37.31M-12.14M-6.66M-14.89M-5.66M-13.69M-12.8M-4.23M-1.46M32.92M65.22M57.18M117.85M78.98M50.81M46.1M28.99M43.1M32.5M31.3M29.1M
Pretax Income-543.8M-380M-460.07M-333.96M-257.99M-29.15M-134.55M338.77M-76.16M-16.76M-57.47M-87.91M-54.39M-66.56M-74.59M-84.79M-61.16M-31.77M-14.52M000000000000
Pretax Margin %-56.66%-40.25%-65.25%-42.4%-43.92%-3.6%-18.45%30.18%-12.7%-3.26%-15.42%-30.99%-25.4%-45.19%-73.09%-85.57%-56.38%-26.12%-13.55%------------
Income Tax-187K1M-6.17M32.32M11.74M-551K345.19M51.51M-291.14M-5.98M2.93M372K-15.41M-5.91M-9.11M11K92K3.19M0000000000000
Effective Tax Rate %0.03%-0.26%1.34%-9.68%-4.55%1.89%-256.55%15.2%382.3%35.67%-5.11%-0.42%28.33%8.89%12.21%-0.01%-0.15%-10.05%0%------------
Net Income-546.14M-381M-453.9M-366.29M-269.72M-28.6M-444.26M278.14M273.74M346K-60.4M-88.28M-38.98M-60.64M-65.48M-84.8M-61.25M155.07M-18.17M-10.99M-45.9M-72.4M-142.5M-95M-72.24M-73.83M-53.48M-59.2M-43M-31.1M-26.5M
Net Margin %-56.9%-40.36%-64.37%-46.5%-45.92%-3.53%-60.92%24.78%45.65%0.07%-16.2%-31.12%-18.2%-41.17%-64.16%-85.58%-56.47%127.52%-16.95%-18.84%-308.92%-180.4%-334.33%-190.03%-90.1%-138.59%-143.56%-174.63%-109.69%-95.11%-116.74%
Net Income Growth %-113.05%16.06%-23.92%-35.8%-843.18%93.56%-259.72%1.61%79015.9%100.57%31.58%-126.45%35.72%7.38%22.79%-38.45%-139.5%953.32%-65.29%76.05%36.6%49.19%-50.01%-31.5%2.15%-38.04%9.65%-37.67%-38.26%-17.36%-11.81%
Net Income (Continuing)-543.62M-381M-453.9M-366.29M-269.72M-28.6M-479.74M287.26M214.99M-10.78M-60.4M-88.28M-38.98M-60.64M-65.48M-84.8M-61.25M-34.96M-14.52M-4.96M-43M-72.4M-142.5M-95M-72.24M-73.83M-53.48M-59.2M-43M-31.1M-26.5M
Discontinued Operations00000000000000000185.63M-8.39M-6.03M-2.9M0000000000
Minority Interest0000000213.45M139.08M84.27M000000010.34M37.16M9.37M29.34M0000000000
EPS (Diluted)-3.29-2.38-3.04-2.56-1.90-0.20-3.182.062.040.15-0.72-0.74-0.33-0.55-0.65-0.85-0.621.58-0.13-0.13-0.62-1.15-2.52-1.71-1.33-1.67-1.44-2.06-1.60-1.17-1.04
EPS Growth %-94.15%21.71%-18.75%-34.74%-850%93.71%-254.37%0.98%1260%120.83%2.7%-124.24%40%15.38%23.53%-37.1%-139.24%1315.38%0%79.03%46.09%54.37%-47.37%-28.57%20.36%-15.97%30.1%-28.75%-36.75%-12.5%5.45%
EPS (Basic)--2.38-3.04-2.56-1.90-0.20-3.182.102.070.15-0.72-0.74-0.33-0.55-0.65-0.85-0.621.58-0.13-0.13-0.62-1.15-2.52-1.71-1.33-1.67-1.44-2.06-1.60-1.17-1.04
Diluted Shares Outstanding166.21M160M149.51M143.19M141.85M141.02M139.61M142.87M134.06M126.1M120.93M119.72M117.69M110.5M100.58M99.66M99.14M98.11M94.57M83.74M74.31M62.88M56.64M55.46M54.48M44.11M37.02M28.7M26.87M26.58M25.48M
Basic Shares Outstanding166.21M160M149.51M143M141.85M141.02M139.61M140M132.32M124.02M120.8M119.29M117.69M110.5M100.58M99.66M99.14M98.11M94.57M83.74M74.31M62.88M56.64M55.46M54.48M44.11M37.02M28.7M26.87M26.58M25.48M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Launch uptake execution shortfall

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Lumpy Revenue Masks Underlying Momentum

As reported in the quarterly income statements, Ionis posted revenue of $242.7M in 2026Q3, up 54.9% year over year, yet the series swings from $452.0M in 2025Q2 to $131.6M in 2025Q1, indicating milestone-driven rather than recurring revenue.

The swing pattern suggests top-line results are dominated by collaboration milestones and upfront recognition rather than a steadily compounding royalty or product base. Reading the 54.9% growth rate in isolation may overstate durability, since the comparison base includes the unusually large 2025Q2 quarter. Investors should monitor whether ex-milestone revenue begins to grow sequentially, which would indicate genuine commercial traction.

High Gross Margin Reflects Licensing Model

Based on reported figures, gross margin held between 96.1% and 99.2% across the ten quarters, with 2026Q3 at 98.6%, a level that reflects the absence of manufacturing-heavy cost of goods rather than operating efficiency.

Such a consistently high gross margin is characteristic of royalty and license income, which carries minimal direct cost, and it should not be read as evidence of pricing power in product manufacturing. The margin profile is likely to compress once self-commercialized products add COGS and distribution costs. Investors should watch for that transition as a structural change in the margin baseline.

Operating Losses Persist Despite Revenue Gains

According to the reported statements, R&D expense of $215.9M in 2026Q3 and SG&A of $154.2M produced an operating loss of $130.7M, a -53.8% operating margin that has not converged toward breakeven across the period.

Operating expenses are scaling roughly in step with revenue rather than lagging it, which indicates negative operating leverage at current revenue levels. The combined R&D and SG&A burden appears to be rising as the company builds a commercial organization. Without a sustained step-up in revenue, the operating cost base appears unlikely to be absorbed in the near term.

Stock Compensation Weighs on Reported Losses

Based on reported figures, stock-based compensation of $43.4M in 2026Q3 equals roughly 18% of the $242.7M revenue base, a meaningful non-cash component embedded within the $110.0M net loss.

A stock compensation charge of this size inflates the reported operating loss relative to cash burn, which is a relevant distinction when assessing funding needs. The 2025Q4 quarter shows no reported SBC, which warrants caution when comparing periods because the data is incomplete. Investors should reconcile net loss against operating cash flow before drawing conclusions about the underlying cost trajectory.

R&D Intensity Anchors the Cost Base

As reported in the quarterly data, R&D expense ran between $200.8M and $280.0M per quarter over the period, consistently exceeding total revenue in most quarters and making R&D the dominant cost driver of the business.

The persistence of R&D at this scale implies that pipeline investment is the primary determinant of operating results rather than commercial activity. Such intensity is typical of a platform company funding late-stage trials, though it leaves little margin for error if pipeline timelines slip. Management's ability to moderate R&D while adding sales capacity will be a key test of expense discipline.

Launch Uptake Could Lag Commercial Assumptions

Based on the supplied commentary, management described TRYNGOLZA's initial sales progress as more gradual than anticipated, a signal that could challenge the revenue ramp assumed by the self-commercialization thesis.

If prescriber adoption and payer access remain slower than planned, the fixed cost of a newly built sales force could deepen operating losses well beyond current levels. Debt-to-equity of 5.35 and return on equity of -70.7% suggest limited balance sheet tolerance for an extended ramp. Investors should treat the commercial transition as unproven until quarterly product revenue demonstrates sustained, non-milestone growth.

IONS — Frequently Asked Questions

Quick answers to the most common questions about buying IONS stock.

What was Ionis Pharmaceuticals, Inc.'s (IONS) revenue in 2025?

For fiscal year 2025, Ionis Pharmaceuticals, Inc. (IONS) reported total revenue of $944.0M. This represents a 4058.6% increase compared to $22.7M in 1996.

Is Ionis Pharmaceuticals, Inc. (IONS) profitable?

Ionis Pharmaceuticals, Inc. (IONS) reported a net loss of $381.0M for the fiscal year ending 2025.

What is Ionis Pharmaceuticals, Inc.'s operating profit margin?

Ionis Pharmaceuticals, Inc. (IONS) reported an operating income of $-382.0M, resulting in an operating profit margin of -40.5%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Ionis Pharmaceuticals, Inc.'s gross profit and gross margin?

Ionis Pharmaceuticals, Inc. (IONS) generated $928.0M in gross profit for the year, representing a gross profit margin of 98.3%. This demonstrates the company's core pricing power and production efficiency.